Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARC JUDAH FISHMAN

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1649317264
CMS profile
29467
Location
BALTIMORE, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$8,000.00

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $8,000.00 1

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Alkermes, Inc. $8,000.00 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARC JUDAH FISHMAN

NPI 1649317264 · CMS profile ID 29467

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

BALTIMORE, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1649317264?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARC JUDAH FISHMAN, NPI 1649317264, CMS profile ID 29467. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1649317264?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). MARC JUDAH FISHMAN, NPI 1649317264, CMS profile ID 29467. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1649317264?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
MARC JUDAH FISHMAN, NPI 1649317264, CMS profile ID 29467, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1649317264?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $8,000.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Alkermes, Inc. $8,000.0004/26/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818239209 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $21,791.29 12
PY2021 $8,000.00 1
PY2022 $9,480.67 2
PY2023 $5,500.00 1
PY2025 $14,575.11 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $6,375.00 1
PY2025 Principal investigator $298,135.39 276
PY2024 Recipient $818.58 1
PY2024 Principal investigator $65,369.26 148
PY2023 Principal investigator $134,098.95 2
PY2021 Principal investigator $96,512.16 9
PY2020 Principal investigator $105,402.16 20
PY2019 Principal investigator $63,619.77 8

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

277 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Indivior Inc. $1,758.00 12/22/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240469203
Principal investigator 1 Indivior Inc. $1,474.00 12/22/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240469205
Principal investigator 1 Indivior Inc. $1,086.00 11/06/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240469075
Principal investigator 1 Indivior Inc. $806.00 10/22/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240469033
Principal investigator 1 Indivior Inc. $134.00 10/22/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240469057
Principal investigator 1 Indivior Inc. $2,980.00 10/22/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240469059
Principal investigator 1 Indivior Inc. $100.00 10/10/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTER
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240468973
Principal investigator 1 Indivior Inc. $793.98 10/10/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTER
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240468975
Principal investigator 1 Indivior Inc. $2,593.00 10/10/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468995
Principal investigator 1 Indivior Inc. $95.00 10/08/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTER
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240468955
Principal investigator 1 Indivior Inc. $95.00 10/08/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTER
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240468957
Principal investigator 1 Indivior Inc. $365.00 10/08/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTER
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240468959
Principal investigator 1 Indivior Inc. $415.00 10/08/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTER
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240468961
Principal investigator 1 Indivior Inc. $297.67 10/08/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTER
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240468963
Principal investigator 1 Indivior Inc. $30.00 10/03/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTER
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240468935
Principal investigator 1 Indivior Inc. $830.00 10/03/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTER
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240468937
Principal investigator 1 Indivior Inc. $214.00 10/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468665
Principal investigator 1 Indivior Inc. $474.50 10/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468667
Principal investigator 1 Indivior Inc. $474.50 10/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468669
Principal investigator 1 Indivior Inc. $474.50 10/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468671
Principal investigator 1 Indivior Inc. $214.00 10/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468673
Principal investigator 1 Indivior Inc. $214.00 10/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468675
Principal investigator 1 Indivior Inc. $214.00 10/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468677
Principal investigator 1 Indivior Inc. $214.00 10/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468679
Principal investigator 1 Indivior Inc. $474.20 10/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468681
Principal investigator 1 Indivior Inc. $474.20 10/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468683
Principal investigator 1 Indivior Inc. $474.20 10/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468685
Principal investigator 1 Indivior Inc. $891.00 10/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468687
Principal investigator 1 Indivior Inc. $214.00 10/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468689
Principal investigator 1 Indivior Inc. $214.00 10/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468691
Principal investigator 1 Indivior Inc. $474.50 10/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468693
Principal investigator 1 Indivior Inc. $474.20 10/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468695
Principal investigator 1 Indivior Inc. $214.00 10/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468697
Principal investigator 1 Indivior Inc. $214.00 10/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468699
Principal investigator 1 Indivior Inc. $474.50 10/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468701
Principal investigator 1 Indivior Inc. $214.00 10/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468703
Principal investigator 1 Indivior Inc. $214.00 10/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468705
Principal investigator 1 Indivior Inc. $214.00 10/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468707
Principal investigator 1 Indivior Inc. $474.20 10/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468709
Principal investigator 1 Indivior Inc. $214.00 10/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468711
Principal investigator 1 Indivior Inc. $214.00 10/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468713
Principal investigator 1 Indivior Inc. $214.00 10/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468715
Principal investigator 1 Indivior Inc. $474.50 10/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468717
Principal investigator 1 Indivior Inc. $3,222.10 08/21/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTER
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240468329
Principal investigator 1 Indivior Inc. $474.50 08/20/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468005
Principal investigator 1 Indivior Inc. $474.50 08/20/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468007
Principal investigator 1 Indivior Inc. $474.50 08/20/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468009
Principal investigator 1 Indivior Inc. $214.00 08/20/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468011
Principal investigator 1 Indivior Inc. $474.50 08/20/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468013
Principal investigator 1 Indivior Inc. $214.00 08/20/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468015
Principal investigator 1 Indivior Inc. $214.00 08/20/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468017
Principal investigator 1 Indivior Inc. $214.00 08/20/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468019
Principal investigator 1 Indivior Inc. $214.00 08/20/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468021
Principal investigator 1 Indivior Inc. $214.00 08/20/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468023
Principal investigator 1 Indivior Inc. $474.50 08/20/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468025
Principal investigator 1 Indivior Inc. $474.50 08/20/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468027
Principal investigator 1 Indivior Inc. $474.50 08/20/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468029
Principal investigator 1 Indivior Inc. $214.00 08/20/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468031
Principal investigator 1 Indivior Inc. $474.50 08/20/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468033
Principal investigator 1 Indivior Inc. $474.50 08/20/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468035
Principal investigator 1 Indivior Inc. $474.50 08/20/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468037
Principal investigator 1 Indivior Inc. $214.00 08/20/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468039
Principal investigator 1 Indivior Inc. $214.00 08/20/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468041
Principal investigator 1 Indivior Inc. $214.00 08/20/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468043
Principal investigator 1 Indivior Inc. $474.50 08/20/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468045
Principal investigator 1 Indivior Inc. $474.50 08/20/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468047
Principal investigator 1 Indivior Inc. $214.00 08/20/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468049
Principal investigator 1 Indivior Inc. $474.20 08/20/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468051
Principal investigator 1 Indivior Inc. $474.20 08/20/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468053
Principal investigator 1 Indivior Inc. $474.20 08/20/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468055
Principal investigator 1 Indivior Inc. $474.20 08/20/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468057
Principal investigator 1 Indivior Inc. $474.20 08/20/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468059
Principal investigator 1 Indivior Inc. $214.00 08/20/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468061
Principal investigator 1 Indivior Inc. $214.00 08/20/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468063
Principal investigator 1 Indivior Inc. $214.00 08/20/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468065
Principal investigator 1 Indivior Inc. $474.20 08/20/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468067
Principal investigator 1 Indivior Inc. $474.20 08/20/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468069
Principal investigator 1 Indivior Inc. $474.20 08/20/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468071
Principal investigator 1 Indivior Inc. $10,881.38 07/24/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTER
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240467751
Principal investigator 1 Indivior Inc. $1,950.00 07/24/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTER
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240467753
Principal investigator 1 Indivior Inc. $214.00 07/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467587
Principal investigator 1 Indivior Inc. $214.00 07/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467589
Principal investigator 1 Indivior Inc. $214.00 07/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467591
Principal investigator 1 Indivior Inc. $214.00 07/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467593
Principal investigator 1 Indivior Inc. $474.20 07/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467595
Principal investigator 1 Indivior Inc. $474.20 07/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467599
Principal investigator 1 Indivior Inc. $214.00 07/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467601
Principal investigator 1 Indivior Inc. $474.50 07/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467603
Principal investigator 1 Indivior Inc. $214.00 07/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467605
Principal investigator 1 Indivior Inc. $214.00 07/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467607
Principal investigator 1 Indivior Inc. $214.00 07/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467609
Principal investigator 1 Indivior Inc. $474.20 07/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467611
Principal investigator 1 Indivior Inc. $214.00 07/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467613
Principal investigator 1 Indivior Inc. $474.20 07/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467615
Principal investigator 1 Indivior Inc. $214.00 07/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467617
Principal investigator 1 Indivior Inc. $214.00 07/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467621
Principal investigator 1 Indivior Inc. $474.20 07/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467623
Principal investigator 1 Indivior Inc. $214.00 07/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467625
Principal investigator 1 Indivior Inc. $214.00 07/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467627
Principal investigator 1 Indivior Inc. $214.00 07/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467629
Principal investigator 1 Indivior Inc. $214.00 07/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467631
Principal investigator 1 Indivior Inc. $214.00 07/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467633
Principal investigator 1 Indivior Inc. $214.00 07/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467635
Principal investigator 1 Indivior Inc. $214.00 07/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467637
Principal investigator 1 Indivior Inc. $214.00 07/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467639
Principal investigator 1 Indivior Inc. $214.00 07/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467643
Principal investigator 1 Indivior Inc. $214.00 07/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467645
Principal investigator 1 Indivior Inc. $214.00 07/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467647
Principal investigator 1 Indivior Inc. $1,266.00 07/07/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467385
Principal investigator 1 Indivior Inc. $2,140.00 07/07/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467387
Principal investigator 1 Indivior Inc. $19,857.72 07/03/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTER
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240467331
Principal investigator 1 Indivior Inc. $214.00 06/26/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467081
Principal investigator 1 Indivior Inc. $474.50 06/26/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467083
Principal investigator 1 Indivior Inc. $214.00 06/26/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467085
Principal investigator 1 Indivior Inc. $214.00 06/26/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467087
Principal investigator 1 Indivior Inc. $214.00 06/26/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467089
Principal investigator 1 Indivior Inc. $214.00 06/26/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467091
Principal investigator 1 Indivior Inc. $214.00 06/26/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467093
Principal investigator 1 Indivior Inc. $214.00 06/26/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467095
Principal investigator 1 Indivior Inc. $474.20 06/26/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467097
Principal investigator 1 Indivior Inc. $214.00 06/26/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467099
Principal investigator 1 Indivior Inc. $214.00 06/26/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467101
Principal investigator 1 Indivior Inc. $474.20 06/26/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467103
Principal investigator 1 Indivior Inc. $214.00 06/26/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467105
Principal investigator 1 Indivior Inc. $474.20 06/26/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467107
Principal investigator 1 Indivior Inc. $214.00 06/26/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467109
Principal investigator 1 Indivior Inc. $214.00 06/26/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467111
Principal investigator 1 Indivior Inc. $214.00 06/26/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467113
Principal investigator 1 Indivior Inc. $214.00 06/26/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467115
Principal investigator 1 Indivior Inc. $214.00 06/26/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467117
Principal investigator 1 Indivior Inc. $214.00 06/26/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467119
Principal investigator 1 Indivior Inc. $214.00 06/26/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467121
Principal investigator 1 Indivior Inc. $214.00 06/26/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467123
Principal investigator 1 Indivior Inc. $214.00 06/26/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467125
Principal investigator 1 Indivior Inc. $891.00 06/26/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467127
Principal investigator 1 Indivior Inc. $891.00 06/26/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467129
Principal investigator 1 Indivior Inc. $891.00 06/26/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467131
Principal investigator 1 Indivior Inc. $891.00 06/26/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467133
Principal investigator 1 Indivior Inc. $891.00 06/26/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467135
Principal investigator 1 Indivior Inc. $891.00 06/26/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467137
Principal investigator 1 Indivior Inc. $474.20 06/26/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467139
Principal investigator 1 Indivior Inc. $474.20 06/26/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467141
Principal investigator 1 Indivior Inc. $214.00 06/26/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467143
Principal investigator 1 Indivior Inc. $474.20 06/26/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467145
Principal investigator 1 Indivior Inc. $214.00 06/26/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467147
Principal investigator 1 Indivior Inc. $214.00 06/26/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467149
Principal investigator 1 Indivior Inc. $900.00 06/18/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240466793
Principal investigator 1 Indivior Inc. $223.41 06/13/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTER
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240466771
Principal investigator 1 Indivior Inc. $9,000.00 06/09/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTER
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240466693
Principal investigator 1 Indivior Inc. $43,806.53 05/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTER
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240466255
Principal investigator 1 Indivior Inc. $474.20 05/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240466391
Principal investigator 1 Indivior Inc. $214.00 05/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240466393
Principal investigator 1 Indivior Inc. $214.00 05/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240466395
Principal investigator 1 Indivior Inc. $214.00 05/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240466397
Principal investigator 1 Indivior Inc. $214.00 05/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240466399
Principal investigator 1 Indivior Inc. $214.00 05/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240466401
Principal investigator 1 Indivior Inc. $474.50 05/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240466403
Principal investigator 1 Indivior Inc. $474.50 05/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240466405
Principal investigator 1 Indivior Inc. $214.00 05/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240466407
Principal investigator 1 Indivior Inc. $214.00 05/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240466409
Principal investigator 1 Indivior Inc. $474.20 05/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240466411
Principal investigator 1 Indivior Inc. $474.20 05/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240466413
Principal investigator 1 Indivior Inc. $474.20 05/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240466415
Principal investigator 1 Indivior Inc. $214.00 05/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240466417
Principal investigator 1 Indivior Inc. $214.00 05/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240466419
Principal investigator 1 Indivior Inc. $214.00 05/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240466421
Principal investigator 1 Indivior Inc. $214.00 05/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240466423
Principal investigator 1 Indivior Inc. $214.00 05/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240466425
Principal investigator 1 Indivior Inc. $214.00 05/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240466427
Principal investigator 1 Indivior Inc. $891.00 05/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240466429
Principal investigator 1 Indivior Inc. $891.00 05/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240466431
Principal investigator 1 Indivior Inc. $891.00 05/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240466433
Principal investigator 1 Indivior Inc. $891.00 05/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240466435
Principal investigator 1 Indivior Inc. $891.00 05/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240466437
Principal investigator 1 Indivior Inc. $891.00 05/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240466439
Principal investigator 1 Indivior Inc. $840.00 05/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240466441
Principal investigator 1 Indivior Inc. $1,280.00 05/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240466443
Principal investigator 1 Indivior Inc. $1,513.00 05/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240466445
Principal investigator 1 Indivior Inc. $469.32 05/22/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTER
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240466229
Principal investigator 1 Indivior Inc. $424.59 05/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTER
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240466127
Principal investigator 1 Indivior Inc. $24,953.66 04/25/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTER
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240466051
Principal investigator 1 Indivior Inc. $214.00 04/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465837
Principal investigator 1 Indivior Inc. $214.00 04/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465839
Principal investigator 1 Indivior Inc. $474.50 04/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465841
Principal investigator 1 Indivior Inc. $214.00 04/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465843
Principal investigator 1 Indivior Inc. $214.00 04/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465845
Principal investigator 1 Indivior Inc. $214.00 04/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465847
Principal investigator 1 Indivior Inc. $214.00 04/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465849
Principal investigator 1 Indivior Inc. $214.00 04/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465851
Principal investigator 1 Indivior Inc. $214.00 04/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465853
Principal investigator 1 Indivior Inc. $214.00 04/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465855
Principal investigator 1 Indivior Inc. $214.00 04/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465857
Principal investigator 1 Indivior Inc. $214.00 04/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465859
Principal investigator 1 Indivior Inc. $214.00 04/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465861
Principal investigator 1 Indivior Inc. $891.00 04/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465863
Principal investigator 1 Indivior Inc. $214.00 04/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465865
Principal investigator 1 Indivior Inc. $891.00 04/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465867
Principal investigator 1 Indivior Inc. $214.00 04/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465869
Principal investigator 1 Indivior Inc. $474.50 04/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465871
Principal investigator 1 Indivior Inc. $474.50 04/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465873
Principal investigator 1 Indivior Inc. $474.50 04/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465875
Principal investigator 1 Indivior Inc. $214.00 04/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465877
Principal investigator 1 Indivior Inc. $214.00 04/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465879
Principal investigator 1 Indivior Inc. $214.00 04/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465881
Principal investigator 1 Indivior Inc. $802.91 04/16/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTER
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240465705
Recipient USWM, LLC $6,375.00 04/03/2025 Covered Recipient Physician A Pharmacokinetic, Safety, and Tolerability Study of LUCEMYRA in the Treatment of Opioid Withdrawal Management in Adolescent Subjects No dispute reported 06/30/2026 1211414832
Principal investigator 1 Indivior Inc. $214.00 04/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465319
Principal investigator 1 Indivior Inc. $214.00 04/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465321
Principal investigator 1 Indivior Inc. $214.00 04/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465323
Principal investigator 1 Indivior Inc. $474.50 04/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465325
Principal investigator 1 Indivior Inc. $214.00 04/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465327
Principal investigator 1 Indivior Inc. $474.20 04/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465329
Principal investigator 1 Indivior Inc. $474.20 04/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465333
Principal investigator 1 Indivior Inc. $214.00 04/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465335
Principal investigator 1 Indivior Inc. $214.00 04/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465337
Principal investigator 1 Indivior Inc. $214.00 04/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465339
Principal investigator 1 Indivior Inc. $891.00 04/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465341
Principal investigator 1 Indivior Inc. $891.00 04/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465343
Principal investigator 1 Indivior Inc. $891.00 04/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465345
Principal investigator 1 Indivior Inc. $891.00 04/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465347
Principal investigator 1 Indivior Inc. $474.50 04/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465349
Principal investigator 1 Indivior Inc. $891.00 04/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465351
Principal investigator 1 Indivior Inc. $214.00 04/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465355
Principal investigator 1 Indivior Inc. $474.50 04/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465357
Principal investigator 1 Indivior Inc. $474.50 04/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465359
Principal investigator 1 Indivior Inc. $474.50 04/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465361
Principal investigator 1 Indivior Inc. $214.00 04/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465363
Principal investigator 1 Indivior Inc. $214.00 04/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465365
Principal investigator 1 Indivior Inc. $214.00 04/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465367
Principal investigator 1 Indivior Inc. $86.00 04/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465369
Principal investigator 1 Indivior Inc. $235.00 04/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465371
Principal investigator 1 Indivior Inc. $1,000.00 04/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465413
Principal investigator 1 Indivior Inc. $1,260.00 04/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465499
Principal investigator 1 Indivior Inc. $1,300.00 04/02/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465517
Principal investigator 1 Indivior Inc. $21,341.50 03/31/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTER
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240465175
Principal investigator 1 Indivior Inc. $1,137.26 03/26/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTER
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240465115
Principal investigator 1 Indivior Inc. $1,003.06 03/05/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTER
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240464860
Principal investigator 1 Indivior Inc. $474.50 03/03/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240464712
Principal investigator 1 Indivior Inc. $214.00 03/03/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240464714
Principal investigator 1 Indivior Inc. $214.00 03/03/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240464716
Principal investigator 1 Indivior Inc. $214.00 03/03/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240464718
Principal investigator 1 Indivior Inc. $474.50 03/03/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240464720
Principal investigator 1 Indivior Inc. $474.50 03/03/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240464722
Principal investigator 1 Indivior Inc. $474.20 03/03/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240464724
Principal investigator 1 Indivior Inc. $474.20 03/03/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240464726
Principal investigator 1 Indivior Inc. $214.00 03/03/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240464728
Principal investigator 1 Indivior Inc. $214.00 03/03/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240464730
Principal investigator 1 Indivior Inc. $214.00 03/03/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240464732
Principal investigator 1 Indivior Inc. $891.00 03/03/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240464734
Principal investigator 1 Indivior Inc. $891.00 03/03/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240464736
Principal investigator 1 Indivior Inc. $30,417.00 02/21/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTER
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240464402
Principal investigator 1 Indivior Inc. $89.47 02/13/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTER
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240464280
Principal investigator 1 Indivior Inc. $214.00 01/28/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240463643
Principal investigator 1 Indivior Inc. $214.00 01/28/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240463645
Principal investigator 1 Indivior Inc. $214.00 01/28/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240463647
Principal investigator 1 Indivior Inc. $214.00 01/28/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240463649
Principal investigator 1 Indivior Inc. $214.00 01/28/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240463651
Principal investigator 1 Indivior Inc. $214.00 01/28/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240463653
Principal investigator 1 Indivior Inc. $214.00 01/28/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240463655
Principal investigator 1 Indivior Inc. $214.00 01/28/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240463657
Principal investigator 1 Indivior Inc. $474.50 01/28/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240463659
Principal investigator 1 Indivior Inc. $214.00 01/28/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240463661
Principal investigator 1 Indivior Inc. $474.50 01/28/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240463663
Principal investigator 1 Indivior Inc. $474.50 01/28/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240463665
Principal investigator 1 Indivior Inc. $214.00 01/28/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240463667
Principal investigator 1 Indivior Inc. $214.00 01/28/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240463669
Principal investigator 1 Indivior Inc. $474.20 01/28/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240463671
Principal investigator 1 Indivior Inc. $214.00 01/28/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240463673
Principal investigator 1 Indivior Inc. $214.00 01/28/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240463675
Principal investigator 1 Indivior Inc. $214.00 01/28/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240463677
Principal investigator 1 Indivior Inc. $214.00 01/28/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240463679
Principal investigator 1 Indivior Inc. $891.00 01/28/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240463681
Principal investigator 1 Indivior Inc. $891.00 01/28/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTERS INC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240463683
Principal investigator 1 Indivior Inc. $134.20 01/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTER
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240463427
Principal investigator 1 Indivior Inc. $5,089.78 01/23/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTER
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240463441
Principal investigator 1 Indivior Inc. $14,045.55 01/08/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTER
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240463069
Principal investigator 1 Indivior Inc. $134.20 01/06/2025 Non-covered Recipient Entity
MARYLAND TREATMENT CENTER
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240463033